Home » News » Drug Sponsors » O’Connor steps down as CEO of Advaxis

O’Connor steps down as CEO of Advaxis

Friday, July 7, 2017

Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of a proprietary Lm-based antigen delivery system, has announced his resignation from the company and its board of directors.

Anthony (Tony) Lombardo will immediately assume the role of interim CEO to continue leading Advaxis in its advancement of multiple cancer immunotherapies based on its proprietary Lm Technology™. Lombardo, who joined the company as chief business officer earlier this year, is an accomplished industry veteran with nearly 30 years of leadership experience in the life sciences industry, including previous positions as president and CEO of E-Z-EM Inc., a NASDAQ listed company, and president of ALI Imaging Systems, Inc. He will serve as interim CEO until a permanent leader is selected.

“I am grateful to have had the opportunity to lead Advaxis for the past several years,” said O’Connor. “The company has powerful technology and a strong management team. I have every confidence in their ability to ensure the company’s continued success.”

Since joining the company as chief executive officer and president in 2013, O’Connor has led Advaxis to the final phase of development for its lead product, spearheaded numerous clinical collaborations, and raised more than $250 million to drive the company’s medical, operational and commercialization plans forward. During his time at Advaxis, O’Connor joined the board of BioNJ and became a leader in the New Jersey biotechnology industry, earning recognition as an EY Entrepreneur of the Year.

“Dan O’Connor has guided Advaxis through a crucial stage in its expansion to become a well-capitalized, NASDAQ-traded company with a burgeoning clinical pipeline and growing scientific and intellectual property assets,” said David Sidransky, chairman of Advaxis’ board. “He has built a strong management team to move the company toward financial success. We thank Dan for his leadership and accomplishments at Advaxis and wish him the best in his future endeavors.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!